Journal ArticleDOI
Global Cancer Incidence and Mortality Rates and Trends—An Update
Reads0
Chats0
TLDR
Applied cancer control measures are needed to reduce rates in HICs and arrest the growing burden in LMICs, as well as for lung, colorectal, breast, and prostate cancer, although some low- and middle-income countries (LMIC) now count among those with the highest rates.Abstract:
There are limited published data on recent cancer incidence and mortality trends worldwide. We used the International Agency for Research on Cancer's CANCERMondial clearinghouse to present age-standardized cancer incidence and death rates for 2003-2007. We also present trends in incidence through 2007 and mortality through 2012 for select countries from five continents. High-income countries (HIC) continue to have the highest incidence rates for all sites, as well as for lung, colorectal, breast, and prostate cancer, although some low- and middle-income countries (LMIC) now count among those with the highest rates. Mortality rates from these cancers are declining in many HICs while they are increasing in LMICs. LMICs have the highest rates of stomach, liver, esophageal, and cervical cancer. Although rates remain high in HICs, they are plateauing or decreasing for the most common cancers due to decreases in known risk factors, screening and early detection, and improved treatment (mortality only). In contrast, rates in several LMICs are increasing for these cancers due to increases in smoking, excess body weight, and physical inactivity. LMICs also have a disproportionate burden of infection-related cancers. Applied cancer control measures are needed to reduce rates in HICs and arrest the growing burden in LMICs.read more
Citations
More filters
Journal ArticleDOI
Cancer treatment and survivorship statistics, 2016.
Kimberly D. Miller,Rebecca L. Siegel,Chun Chieh Lin,Angela B. Mariotto,Joan L. Kramer,Julia H. Rowland,Kevin Stein,Rick Alteri,Ahmedin Jemal +8 more
TL;DR: The number of cancer survivors continues to increase because of both advances in early detection and treatment and the aging and growth of the population and for the public health community to better serve these survivors, the American Cancer Society and the National Cancer Institute collaborate to estimate the number of current and future cancer survivors.
Journal ArticleDOI
Occurrence of the potent mutagens 2- nitrobenzanthrone and 3-nitrobenzanthrone in fine airborne particles
TL;DR: In the present study, 2-NBA, 3-NBA and selected PAHs and Nitro-PAHs were determined in fine particle samples collected in a bus station and an outdoor site, showing low cancer risk incidence and incremental lifetime cancer risk (ILCR) calculated for both places.
Journal ArticleDOI
Clinical practice guidelines in oncology
William J. Gradishar,Benjamin O. Anderson,Ron Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Janice A. Lyons,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Meena S. Moran,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Amy Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Rashmi Kumar,Dorothy A. Shead +32 more
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Journal ArticleDOI
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Kohei Shitara,Yung-Jue Bang,Satoru Iwasa,Naotoshi Sugimoto,Min-Hee Ryu,Daisuke Sakai,Hyun-Cheol Chung,Hisato Kawakami,Hiroshi Yabusaki,Jeeyun Lee,Kaku Saito,Yoshinori Kawaguchi,Takahiro Kamio,Akihito Kojima,Masahiro Sugihara,Kensei Yamaguchi,DESTINY-Gastric Investigators +16 more
TL;DR: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based lin...
Journal ArticleDOI
Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.
Douglas E. Wood,Ella A. Kazerooni,Scott Baum,Georgie A. Eapen,David S. Ettinger,Lifang Hou,David M. Jackman,Donald Klippenstein,Rohit Kumar,Rudy P. Lackner,Lorriana E. Leard,Inga T. Lennes,Ann N. Leung,Samir S. Makani,Pierre P. Massion,Peter J. Mazzone,Robert E. Merritt,Bryan F. Meyers,David E. Midthun,Sudhakar Pipavath,Christie Pratt,Chakravarthy Reddy,Mary E. Reid,Arnold J. Rotter,Peter B. Sachs,Matthew B. Schabath,Mark L. Schiebler,Betty C. Tong,William D. Travis,Benjamin Wei,Stephen C. Yang,Kristina M. Gregory,Miranda Hughes +32 more
TL;DR: This manuscript focuses on identifying patients at high risk for lung cancer who are candidates for low-dose computed tomography of the chest and on evaluating initial screening findings.
References
More filters
Journal ArticleDOI
Comparison of fecal occult blood tests for colorectal cancer screening in an Alaska Native population with high prevalence of Helicobacter pylori infection, 2008-2012.
Diana Redwood,Ellen Provost,Elvin Asay,Diana Roberts,Donald Haverkamp,David G. Perdue,Michael G. Bruce,Frank Sacco,David K. Espey +8 more
TL;DR: The iFOBT represents a potential strategy for expanding CRC screening among Alaska Native and other populations with elevated prevalence of H. pylori, especially where access to screening endoscopy is limited.